Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Paz

Showing results (251-260 of 258) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 258 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2024
Lung cancer research and treatment: global perspectives and strategic calls to actionM-L Meyer, S Peters, T S Mok, et al.
ESMO Open|August 20, 2022
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter studyM Simonelli, E Garralda, F Eskens, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 3, 2016
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapyJ De Castro, J L González-Larriba, S Vázquez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
ESMO Open|October 1, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trialE Seguí, F Brasó-Maristany, T Pascual, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
Neuroscience and Biobehavioral Reviews|July 19, 2019
Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confoundersYang Liu, Wery P M van den Wildenberg, Ysanne de Graaf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)H J Schmoll, R Souchon, S Krege, et al.
Pageof 26

Showing results (251-260 of 258) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 258 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2024
Lung cancer research and treatment: global perspectives and strategic calls to actionM-L Meyer, S Peters, T S Mok, et al.
ESMO Open|August 20, 2022
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter studyM Simonelli, E Garralda, F Eskens, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 3, 2016
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapyJ De Castro, J L González-Larriba, S Vázquez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2022
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancerA Passaro, N Leighl, F Blackhall, et al.
ESMO Open|October 1, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trialE Seguí, F Brasó-Maristany, T Pascual, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
Neuroscience and Biobehavioral Reviews|July 19, 2019
Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confoundersYang Liu, Wery P M van den Wildenberg, Ysanne de Graaf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)H J Schmoll, R Souchon, S Krege, et al.
Pageof 26